Genmab CEO expects more legal twists in future

Danish biotech company Genmab is currently awaiting the verdict from an arbitration dispute with partner Johnson & Johnson. CEO at Genmab Jan van de Winkel sees an increased chance of more legal cases in the future, as the company continues to grow.
Photo: Tuala Hjarnø / Genmab / PR
Photo: Tuala Hjarnø / Genmab / PR
by ANDREAS LØNSTRUP, translated by daniel pedersen

As Genmab gets bigger on all parameters, so too increases the attention from lawyers and legal departments from competitors across the globe, says CEO of Genmab Jan van de Winkel, as reported by Danish business daily Børsen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading